We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+3.46%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
-$141M
Cap. Flow
+$96.9M
Cap. Flow %
2.89%
Top 10 Hldgs %
41.69%
Holding
77
New
11
Increased
22
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$68M
2
APLS
Apellis Pharmaceuticals
APLS
+$67.9M
3
TGTX icon
TG Therapeutics
TGTX
+$45.8M
4
KRRO icon
Korro Bio
KRRO
+$42.6M
5
AXSM icon
Axsome Therapeutics
AXSM
+$40.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$108M
2
GERN icon
Geron
GERN
+$68.2M
3
APGE icon
Apogee Therapeutics
APGE
+$64.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
5
TRML
Tourmaline Bio
TRML
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.19B
$51.1M 1.52%
+2,870,131
New +$45.8M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.2B
$51M 1.52%
3,923,849
+467,796
+14% +$6.48M
KYMR icon
28
Kymera Therapeutics
KYMR
$8.66B
$44.8M 1.34%
1,500,000
+237,754
+19% +$8.23M
DFTX
29
Definium Therapeutics
DFTX
$5.6B
$44M 1.31%
6,103,817
-562,850
-8% -$4.92M
OLMA icon
30
Olema Pharmaceuticals
OLMA
$977M
$43.3M 1.29%
4,000,000
+774,581
+24% +$8.4M
TERN
31
DELISTED
Terns Pharmaceuticals
TERN
$41.5M 1.24%
6,100,000
– –
SYRE icon
32
Spyre Therapeutics
SYRE
$8.5B
$41.3M 1.23%
1,756,667
+543,247
+45% +$18.3M
APGE icon
33
Apogee Therapeutics
APGE
$10.1B
$39.4M 1.17%
1,000,000
-1,323,456
-57% -$64.2M
GPCR icon
34
Structure Therapeutics
GPCR
$3.37B
$37.3M 1.11%
950,000
+909,863
+2,267% +$37.4M
ANIP icon
35
ANI Pharmaceuticals
ANIP
$1.86B
$29.7M 0.89%
466,089
-355,912
-43% -$23.1M
EDIT icon
36
Editas Medicine
EDIT
$399M
$28M 0.84%
6,000,000
+472,710
+9% +$2.67M
CLYM
37
Climb Bio
CLYM
$693M
$27.8M 0.83%
+3,904,785
New +$26M
HLVX
38
DELISTED
HilleVax
HLVX
$26.5M 0.79%
1,832,652
-739,808
-29% -$10.2M
KRRO icon
39
Korro Bio
KRRO
$145M
$26.1M 0.78%
+770,645
New +$42.6M
SLN
40
Silence Therapeutics
SLN
$546M
$25.8M 0.77%
1,359,745
-284,136
-17% -$6.04M
NKTR icon
41
Nektar Therapeutics
NKTR
$2.39B
$22.2M 0.66%
1,191,700
-34,967
-3% -$737K
ENGN icon
42
enGene Therapeutics
ENGN
$120M
$21.2M 0.63%
2,250,000
– –
ALEC icon
43
Alector
ALEC
$169M
$21M 0.63%
4,631,998
+862,612
+23% +$4.44M
ETNB
44
DELISTED
89bio
ETNB
$18.4M 0.55%
+2,294,011
New +$20.5M
FATE icon
45
Fate Therapeutics
FATE
$275M
$18.3M 0.55%
5,572,607
– –
INO icon
46
Inovio Pharmaceuticals
INO
$85.6M
$16.7M 0.5%
+2,066,720
New +$21.7M
PRAX icon
47
Praxis Precision Medicines
PRAX
$8.11B
$16.1M 0.48%
+389,546
New +$18.4M
HELP
48
Cybin Inc
HELP
$490M
$15.8M 0.47%
1,529,988
– –
CNTX icon
49
Context Therapeutics
CNTX
$56.7M
$14.9M 0.44%
+7,419,355
New +$12.8M
PYXS icon
50
Pyxis Oncology
PYXS
$185M
$13.8M 0.41%
4,184,100
– –
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Deep Track Capital held 77 positions worth $3.35B, down 4% from $3.49B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital's Q2 2024 filing shows 11 new, 22 increased, 20 reduced and 9 closed positions. Its largest new stake was TG Therapeutics: 2,870,131 shares worth $51.1M. The largest sale was Insmed, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Deep Track Capital's largest Q2 2024 buy was TG Therapeutics: 2,870,131 shares worth $51.1M.
  • Deep Track Capital added most to Immunovant in Q2 2024, an estimated $68M increase.
  • Deep Track Capital's biggest Q2 2024 reduction was Insmed, cutting an estimated $108M.
  • Deep Track Capital fully exited Tourmaline Bio in Q2 2024, selling an estimated $36.5M.
  • Deep Track Capital's ten largest holdings make up 42% of its $3.35B portfolio in Q2 2024.
  • Deep Track Capital opened 11 new positions and closed 9 in Q2 2024.
  • Deep Track Capital's portfolio value fell 4% quarter-over-quarter to $3.35B.

Based on Deep Track Capital's 13F filing for Q2 2024, filed 14 Aug 2024.